about
Protein glycosylation in cancers and its potential therapeutic applications in neuroblastomaCOSMC is overexpressed in proliferating infantile hemangioma and enhances endothelial cell growth via VEGFR2.B4GALNT3 expression predicts a favorable prognosis and suppresses cell migration and invasion via β₁ integrin signaling in neuroblastoma.Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylationA multidisciplinary team care approach improves outcomes in high-risk pediatric neuroblastoma patients.Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma.The alpha (1,3)-fucosyltransferase Fuc-TIV, but not Fuc-TVII, generates sialyl Lewis X-like epitopes preferentially on glycolipids.β-1,4-Galactosyltransferase III suppresses extravillous trophoblast invasion through modifying β1-integrin glycosylation.Calreticulin activates β1 integrin via fucosylation by fucosyltransferase 1 in J82 human bladder cancer cells.B3GNT3 expression suppresses cell migration and invasion and predicts favorable outcomes in neuroblastoma.β-1,4-Galactosyltransferase III enhances invasive phenotypes via β1-integrin and predicts poor prognosis in neuroblastoma.Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma.GATA3 interacts with and stabilizes HIF-1α to enhance cancer cell invasiveness.GATA3 interacts with and stabilizes HIF-1α to enhance cancer cell invasiveness.Calreticulin mediates nerve growth factor-induced neuronal differentiation.The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activitiesLactoferrin promotes hair growth in mice and increases dermal papilla cell proliferation through Erk/Akt and Wnt signaling pathways.C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancerSilencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway
P50
Q28069952-16393E20-DFAE-4E33-933C-BD1F173D2C93Q34592757-6AC3845A-F5FC-4ED8-9BC8-F55832F129AFQ35168043-CE712B31-21CC-4123-9A38-9594D88BCAFEQ36998213-CA4A220E-5AEA-493C-85F0-26D88E1E1377Q37706191-A6991DF0-509B-4B08-88D3-511A67F590FDQ38331885-60620C8F-9B60-45D2-B8D4-86AB662FF690Q38362343-13F6E53E-D8D6-489C-B4BB-A7BE8CC6EAE4Q38912222-13268B12-74F1-4619-A268-372AE9240355Q39018762-93067E6C-B4CA-47C3-AF9B-D55F9D502FD1Q39080654-B04DAE80-8A5D-4A58-9574-0DECAB500C6FQ39187979-BEF8479F-6F3B-4909-860B-C73BE7B8339AQ39459644-740D0E5A-94DA-4E58-B3F5-FBC3AF1FFA03Q39663736-1EBA0A95-1FA8-447A-B6B6-5254A96294E0Q41193866-CF7314C4-84C2-457C-8B98-C6AAEA343C00Q42340486-0EDB8C29-E357-471A-AB3A-19F5E3DBBAE2Q54544993-2FEE3CF9-89CC-4686-8EB7-2041D94BE882Q57494132-70AC8D35-DB67-469B-AF42-A96D6730FD17Q64916345-F8CAAC76-70D9-4859-86DA-D48A5E1C02A1Q89181641-49124380-C29A-49AC-A2A8-762B5F8EFA87Q89545812-930A9146-1884-4E13-8AD0-01BFDA28069C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Min-Chuan Huang
@ast
Min-Chuan Huang
@en
Min-Chuan Huang
@es
Min-Chuan Huang
@nl
type
label
Min-Chuan Huang
@ast
Min-Chuan Huang
@en
Min-Chuan Huang
@es
Min-Chuan Huang
@nl
prefLabel
Min-Chuan Huang
@ast
Min-Chuan Huang
@en
Min-Chuan Huang
@es
Min-Chuan Huang
@nl
P106
P1153
56301224700
7404260546
P31
P496
0000-0002-0704-3447